Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2014 02:36 ET | Source: Active Biotech

Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease

LUND, Sweden, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to...
August 14, 2014 02:30 ET | Source: Active Biotech

Active Biotechs partner Teva startar en klinisk studie med laquinimod i Huntingtons sjukdom

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sverige den 14 augusti 2014 - Active...
August 14, 2014 02:30 ET | Source: Active Biotech

Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sweden, August 14, 2014 - Active Biotech...
August 07, 2014 02:36 ET | Source: Active Biotech

Active Biotech AB Interim report January-June 2014

LUND, Sweden, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Laquinimod On May 23, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) reaffirmed its negative opinion on the...
August 07, 2014 02:30 ET | Source: Active Biotech

Active Biotech AB Delårsrapport januari - juni 2014

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod Laquinimod (Nerventra®) erhöll den...
August 07, 2014 02:30 ET | Source: Active Biotech

Active Biotech AB Interim report January-June 2014

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod On May 23, the European Medicines...
June 11, 2014 02:36 ET | Source: Active Biotech

Active Biotech presents data on paquinimod at EULAR 2014

LUND, Sweden, June 11, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data related to the drug candidate paquinimod (57-57) for the treatment of systemic sclerosis, at...
June 11, 2014 02:30 ET | Source: Active Biotech

Active Biotech presenterar data för paquinimod på EULAR 2014

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 11 juni 2014, Active Biotech (NASDAQ OMX...
June 11, 2014 02:30 ET | Source: Active Biotech

Active Biotech presents data on paquinimod at EULAR 2014

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sweden, June 11, 2014, Active Biotech...
June 03, 2014 02:35 ET | Source: Active Biotech

Active Biotech to Present at Jefferies 2014 Healthcare Conference

LUND, Sweden, June 3, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at Jefferies 2014 Healthcare Conference held June 2-5, 2014 in New York, US. During the...